- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer
May 13, 2024
Video
Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.
Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma
May 13, 2024
Video
Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.
The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
May 13, 2024
Article
Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.
EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
May 10, 2024
Article
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
New $15 Million Grant to Dana-Farber Scientists Supports Research into Innovative Approaches to Endometrial Cancer Treatment
May 10, 2024
Article
Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
May 06, 2024
Article
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL
May 06, 2024
Article
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
May 02, 2024
Article
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
May 02, 2024
Video
Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.
Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma
April 29, 2024
Video
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study
April 25, 2024
Article
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
April 25, 2024
Article
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Study Provides a First Look at Oncologists' Views on Ethical Implications of AI in Cancer Care
April 19, 2024
Article
In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
April 18, 2024
Article
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
April 17, 2024
Article
Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.
Dana-Farber Cancer Institute Earns Fifth Consecutive Magnet® Designation Recognizing Excellence in Nursing Practice and Patient Care
April 15, 2024
Article
The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.
Dr Park on the Initial Efficacy of Epacadostat Plus Preoperative Chemoradiation in Rectal Cancer
April 11, 2024
Video
Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.
Insider Insights: Unveiling Takeaways from AACR 2024
April 11, 2024
Article
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL
April 09, 2024
Video
Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.